Dulaglutide, semaglutide, and tirzepatide exhibit comparable gastrointestinal adverse event risk
1. In this cohort study, dulaglutide, semaglutide, and tirzepatide demonstrated similar risks of gastrointestinal adverse events (AEs) in…
Closing the gap in HCV care: strategic collaboration between industry, academic, community, and nonprofit researchers
Simplified care cascades with easier treatment access are needed to ensure optimal treatment uptake with minimal patient loss…
Cholecystitis and cholangiocarcinoma: a two-sample Mendelian randomization study | BMC Gastroenterology
This study represents the first study to systematically evaluate the causal link between genetic susceptibility to cholecystitis and…
Investigating the shared genetic information between serum concentration levels of liver enzymes and cholelithiasis | BMC Gastroenterology
GWAS summary data Genome-wide association study (GWAS) summary statistics were obtained from three publicly available databases: OPEN GWAS…